Medscape September 11, 2024
Edited by Shrabasti Bhattacharya

TOPLINE:

MADRID — Elevated interleukin (IL) 6 levels are associated with an increased risk for obesity-related cancers in patients newly diagnosed with type 2 diabetes (T2D), potentially enabling the identification of higher-risk individuals through a simple blood test.

METHODOLOGY:

  • T2D is associated with an increased risk for obesity-related cancers, including breast, renal, uterine, thyroid, ovarian, and gastrointestinal cancers, as well as multiple myeloma, possibly because of chronic low-grade inflammation.
  • Researchers explored whether the markers of inflammation IL-6, tumor necrosis factor alpha (TNF-α), and high-sensitivity C-reactive protein (hsCRP) can serve as predictive biomarkers for obesity-related cancers in patients recently diagnosed with T2D.
  • They identified patients with recent-onset T2D and no prior history of cancer participating in the ongoing Danish Centre...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Patient / Consumer, Provider
Related Articles:
Where hospitals, health systems fall short in ASC joint ventures
AI's role in stroke care at Orlando Health, 2 years in
Mapped: Life Expectancy in Major Economies
Up to 4 in 10 people could develop dementia after 55. What you can do to lower your risk
'We need to be here': Minnesota hospital critical-access status at risk

Share This Article